Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473047 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL200462 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL18914987 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL1005092 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL18218788 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL18219056 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL23296774 | 0.81 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL183678 | 0.81 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL8775286 | 0.81 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL2280018 | 0.81 | GLS (0.46) | GLSBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099793-B1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8063224-B2 | [5-(5-{4-[2-(Trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | GLS 578/4885BACE1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.